Axel Nierhaus
University of Hamburg
109 Papers
291 Citations
Axel Nierhaus is an academic researcher from University of Hamburg. The author has contributed to research in topics: Medicine & Sepsis. The author has an hindex of 29, co-authored 94 publications.
Chat about Author
Papers
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.
Dominic Wichmann,Jan-Peter Sperhake,Marc Lütgehetmann,Stefan Steurer,Carolin Edler,Axel Heinemann,Fabian Heinrich,Herbert Mushumba,Inga Kniep,Ann Sophie Schröder,Christoph Burdelski,Geraldine de Heer,Axel Nierhaus,Daniel Frings,Susanne Pfefferle,Heinrich Becker,Hanns Bredereke-Wiedling,Andreas de Weerth,Hans-Richard Paschen,Sara Sheikhzadeh-Eggers,Axel Stang,Stefan Schmiedel,Carsten Bokemeyer,Marylyn M. Addo,Martin Aepfelbacher,Klaus Püschel,Stefan Kluge +26 more
TL;DR: In this paper, the causes of COVID-19-related deaths were investigated in a single academic medical center in the German federal state of Hamburg for patients dying with a polymerase chain reaction-confirmed diagnosis of CoV-19 patients.
2.2K
Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock.
TL;DR: A meta‐analysis of all published randomized controlled studies published on polyvalent immunoglobulins (Ig) for treatment of sepsis or septic shock in adults, children, or neonates found a trend in favor of IgGAM.
278
Sepsis-Pathophysiology and Therapeutic Concepts.
TL;DR: In this article, the authors provide an overview of sepsis immune pathophysiology, update the choice of therapeutic approaches targeting different immunological mechanisms, and call for a paradigm shift from the pathogen to the host response as a potentially more promising angle.
Effect of Empirical Treatment With Moxifloxacin and Meropenem vs Meropenem on Sepsis-Related Organ Dysfunction in Patients With Severe Sepsis: A Randomized Trial
Frank M. Brunkhorst,Michael Oppert,Gernot Marx,Frank Bloos,Katrin Ludewig,Christian Putensen,Axel Nierhaus,Ulrich Jaschinski,Andreas Meier-Hellmann,Andreas Weyland,Matthias Gründling,Onnen Moerer,Reimer Riessen,Armin Seibel,Maximilian Ragaller,Markus W. Büchler,Stefan John,Friedhelm Bach,Claudia Spies,Lorenz Reill,Harald Fritz,Michael Kiehntopf,Evelyn Kuhnt,Holger Bogatsch,Christoph Engel,Markus Loeffler,Marin H. Kollef,Konrad Reinhart,Tobias Welte +28 more
TL;DR: In this paper, the authors compared the effect of moxifloxacin and meropenem with the effect on sepsis-related organ dysfunction and concluded that meropenems alone did not result in less organ failure.
230
Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis The HYPRESS Randomized Clinical Trial
Didier Keh,Evelyn Trips,Gernot Marx,Stefan Wirtz,Emad Abduljawwad,Sven Bercker,Holger Bogatsch,Josef Briegel,Christoph Engel,Herwig Gerlach,Anton Goldmann,Sven-Olaf Kuhn,Lars Hüter,Andreas Meier-Hellmann,Axel Nierhaus,Stefan Kluge,Josefa Lehmke,Markus Loeffler,Michael Oppert,Kerstin Resener,Dirk Schädler,Tobias Schuerholz,Philipp Simon,Norbert Weiler,Andreas Weyland,Konrad Reinhart,Frank M. Brunkhorst +26 more
TL;DR: Among adults with severe sepsis not in septic shock, use of hydrocortisone compared with placebo did not reduce the risk of septicshock within 14 days, and these findings do not support the use ofHydroc Cortisone in these patients.